Comparative Pharmacology
Head-to-head clinical analysis: VALPROIC ACID versus ZARONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALPROIC ACID versus ZARONTIN.
VALPROIC ACID vs ZARONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
Ethosuximide (Zarontin) suppresses paroxysmal 3 Hz spike-and-wave activity associated with absence seizures. The mechanism may involve inhibition of T-type calcium channels in thalamic neurons, reducing oscillatory burst firing.
Initial: 10-15 mg/kg/day orally (divided 2-3 times), increase by 5-10 mg/kg/week; maintenance: 30-60 mg/kg/day. IV infusion: same oral dose, rate ≤20 mg/min.
500 mg orally twice daily initially; may increase by 250 mg every 4-7 days. Maintenance: 1000-1500 mg/day in 2 divided doses; maximum 1500 mg/day.
None Documented
None Documented
Clinical Note
moderateValproic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Valproic acid is combined with Fluticasone propionate."
Clinical Note
moderateValproic acid + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Valproic acid."
Clinical Note
moderateValproic acid + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Valproic acid."
Clinical Note
moderateValproic acid + Fluconazole
Terminal elimination half-life is 9–16 hours in adults; shorter in children (6–9 hours) and longer in neonates (20–30 hours), elderly, or hepatic impairment (up to 18 hours).
60 hours (range 40-70) in adults; 30-40 hours in children (due to higher clearance); clinical context: steady-state reached in ~10-14 days; may be reduced with enzyme-inducing co-medications.
Primarily hepatic metabolism (>95%), with less than 3% excreted unchanged in urine. Minor fecal excretion (~5%).
Renal: ~40% as unchanged drug; hepatic metabolism accounts for ~60% (primarily via CYP3A4, forming inactive metabolites); <1% fecal.
Category D/X
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Valproic acid."